Revolutionary Nasal Vaccines: New glimmer against Covid-19!
Revolutionary Nasal Vaccines: New glimmer against Covid-19!
Scientists work on a new generation of mucosal vaccines that could prove to be valuable in the fight against Covid-19. Such a concept was developed by a nasal viral vector vaccine based on the harmless Newcastle Disease Virus (NDV), which does not cause illness in humans. This vaccine expresses a stabilized spike protein from SARS-COV-2 to trigger an immune response. According to Kleine Zeitung , the tissue distribution, immunogenicity and the vaccination protection of this trivalent vector vaccine became the variants of Wuhan, Beta and Delta Again, examined in both mice and gold hamsters.
Research shows promising results: The trivalent vector residual vaccine, which was administered intranasally, showed a limited replication and mostly remained at the location, which made it more effective than injected variants. In the infection tests carried out, it was observed that none of the vaccinated golden hamsters are ill. In addition, the vaccine cross-room tunity with the Omicron variant BA.1, which increases its relevance in combating Covid-19.
Development of vaccines
The existing SARS-COV-2 vaccines have their strengths, especially when preventing serious illnesses, but there are still challenges in induction of protective mucosal immunity. In this context, intranasal vaccines are important that aim to stop the transmission of respiratory viruses. According to a study , NDV vectors are promising, since they are an inexpensive and immunogenic platform for vaccines that are stable at temperatures above the freezing point of the freezing. uses. Phase 1 and 2 clinical studies on NDV-S vaccines already show security and immunogenicity, while phase 3 studies are still standing.
The study emphasizes that currently used mRNA vaccines are only able to generate immune responses in the upper respiratory tract, which underlines the need for new vaccines. An ongoing development is required, especially to achieve strong mucosal immune responses.
results and outlook
In addition, it was found in another study that the NDV-Vectored vaccine (NDV-FLS) offers significant protective effect against SARS-COV-2 by significantly reducing the viral load and the disease manifestation. In experiments with cynomolgus monkeys, the vaccine showed that after two doses he triggered robust immune responses via respiratory immunization and reduced the viral RNA values in nasal drawbacks and lower airways. The results indicate that the NDV vector is a promising candidate for clinical development. In summary, the research results provide a promising proof of feasibility for mucosal, multivalent NDV-HXP-S vaccines that could be considered as future COVID 19-booster. These developments could make the constant adaptation of new variants superfluous and offer effective prevention against future pandemics.| Details | |
|---|---|
| Ort | National Microbiology Laboratory, Public Health Agency of Canada, Kanada |
| Quellen | |
Kommentare (0)